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Blake Drains as chest tubes in lung resection patients
Nitadori, Jun-Ichi; Yoshida, Junji; Nishimura, Mituyo; Nagai, Kanji 
Thoracic Oncology Division, National Cancer Center Hospital East, 
Chiba-Ken, Japan
Background: In Japan, an increasing number of surgeons use a Blake 
Drain (Ethicon, Somerville, NJ) as a chest tube after lung resection to 
reduce the removal workload. However, optimum Blake Drain length 
and placement has not been established, nor removal wound closure 
method. We started using Blake Drains in August 2002 in place of 
traditional chest tubes after lung resection.
Objective: Evaluate use of a single 19 Fr Blake Drain in place of a 
single 28/32 Fr chest tube after lung resection. Compare two Blake 
Drain lengths and placement. Evaluate Blake Drain removal without 
tube wound suturing.
Methods: At the National Cancer Center Hospital East, from August 
2002 through December 2006, we used a single 19 Fr Blake Drain for 
chest cavity drainage in 450 consecutive patients undergoing lung re-
section. Initially, until August 2004, the Blake Drain was inserted at the 
7th intercostal space, up along the vertebrae, to the chest cavity apex 
(short type: ST). From September 2004, a longer Blake Drain was used, 
running to the apex and then turning down the front chest wall, almost 
reaching the diaphragm (long type: LT). 
Results: There were 273 men and 177 women. Of them, 396 patients 
underwent lung resection for primary lung cancer, 37 for metastatic 
cancer, and 17 for various benign diseases. Three patients underwent 
bilateral thoracotomy, and 453 Blake Drains were placed. Length dis-
tribution was almost evenly split with 222 ST and 231 LT Blake Drains 
placed. Three hundred and thirty-six patients underwent lobectomy 
(ST: 171, LT: 165), 20 bilobectomy (ST: 7, LT: 13), 19 pneumonectomy 
(ST: 9, LT: 10), 7 segmentectomy (ST: 3, LT: 4), 67 wedge resection 
(ST: 19, LT: 48), and 4 exploratory thoracotomy (ST: 3, LT: 1).
The Blake Drains were removed an average of 4 (range 1-21) days after 
surgery. We had the, not unusual, complications of tube obstruction or 
massive subcutaneous emphysema due to poor air drainage, but nothing 
unique to the Blake Drain. Tube obstruction occurred in 37 (16.7%) ST 
patients and in 3 (1.3%) LT patients (p<0.001). We replaced the Blake 
Drain with trocar tubes due to obstruction or massive subcutaneous 
emphysema in 5 (2.3%) ST patients and 4 (1.7%) LT patients (p=0.69). 
The Blake Drain removal wounds were sutured in 59 (26.6%) ST 
patients and 14 (6.1%) LT patients (p<0.001). 
Summary: Tube obstruction occurred signiﬁcantly more frequently 
in ST patients. However, there was no difference in the need for Blake 
Drain replacement between ST and LT patients. Initially we were not 
conﬁdent in using just tape and leaving the removal wound un-sutured 
so more ST patients had removal wound suturing. Less than 10% of the 
LT patients needed suturing. This occurred mostly if the Blake Drain 
was in for a long period.
Conclusions: Blake Drains in the Long Tube placement showed good 
drainage capability in lung resection patients. Most patients did not 
need Blake Drain removal wound suturing. This saves considerable 
surgeon’s time.
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Predictive utilisation and associated costs of bevacuzimab with 
chemotherapy in advanced NSCLC
Noonan, Anne M.; Dempsey, Karen; Murray, Michael R.; Priggs,  
Margaret M.; Grogan, Liam; Breathnach, Oscar S. 
Beaumont Hospital / Cancer Centre, Dublin, Ireland
Background: The cost of systemic cancer therapies continues to 
increase and is a major concern to those funding these therapies. Novel 
therapeutics continue to show additional beneﬁt when combined with 
systemic therapies. Our aim was to assess the potential cost impact 
of adding bevacizumab to chemotherapy as per the eligibility criteria 
of the ECOG E4599 trial (Carboplatin, Paclitaxel & Bevacizumab; 
Sandler et al NEJM 2006; 355; 2542-50).
Methods: All patients with NSCLC seen in the clinic of one medical 
oncologist over a 1 year period were assessed. Patients with stage IIIB 
(with malignant pleural effusion), stage IV or recurrent NSCLC were 
selected for consideration. Patients’ records were assessed for inclu-
sion/exclusion criteria as per E4599. Costings for bevacizumab were as 
per epocrates.com quotations ($646 per 100mg).
Results: 49 of 87 patients were eligible for assessment. The male to 
female ratio was 2.5:1. Only 6% (3) of patients were eligible for the 
protocol with bevacizumab. Most patients had at least one of the 12 
exclusion criteria or failed to meet all of the 6 inclusion criteria. The 
top 5 most common exclusion criteria are shown in table 1. 
Exclusion Criteria Patient Numbers (%)
Squamous NSCLC 23 (47%)
NSAIDs / Antiplatelet therapy 14 (29%)
Radiotherapy within 21 days 11 (22%)
Clinically signiﬁcantly cardiovasculr disease 7 (14%)
CNS metastases 6 (12%)
28.5% of patients had an ECOG performance status of >1 and therefore 
failed to meet this inclusion criterion. 
Conclusion: The vast majority of patients with advanced NSCLC 
would not have been eligible for the addition of bevacizumab to 
chemotherapy. With only 6% of patients eligible, the anticipated direct 
drug cost for inclusion of bevacizumab into standard care was lower 
than expected. For an average 70kg male the addition of bevacizumab 
15mg/kg to 6 cycles of chemotherapy would cost an extra $40,698 
and for an average 55kg female the cost is $31,977. If an additional 5 
cycles of bevacizumab monotherapy are given (average until disease 
progression in E4599) the additional costs would be another $33,915 
for males and $26,647 for females. Judicious use of bevacizumab in 
advanced NSCLC shows a doubling in survival at 2 years (from 8 to 
15%) in this highly selected group as per E4599. The additional cost is 
acceptable in this limited population.
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The role of the nurse practitioner thorax oncology in the 
Netherlands
Olijve, Albert; Burgers, Jacobus A. 
Netherlands Cancer Institute, Amsterdam, The Netherlands
Background: The nurse practitioner is a specialized nurse. In his 
professional approach he is able to take over some roles from the 
specialist. He integrates nursing care and medical care. In the 1960s 
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and 1970s the nurse practitioner became a new professional in the USA 
by reason of shortage of primary care physicians. Van Offenbeek et al 
(2003) described the effects of the embedding of the nurse practitioner 
in the health system in the Netherlands. The main part of the role of 
the nurse practitioner was the coordination of patient care, performing 
medical acts, consultation and keeping medical consulting hours. In ad-
dition, the role of the nurse practitioner seemed particularly suitable to 
integrate the nursing and medical and social aspects of patient care.
Only in 1997, the ﬁrst nurse practitioner education in the Netherlands 
was established, and in 2001 the Netherlands Cancer Institute-Antoni 
van Leeuwenhoek Hospital appointed its ﬁrst nurse practitioner. The 
nurse practitioner thorax oncology started in February 2004. 
The nurse practitioner is a member of the thoracic oncology group, 
consisting of dedicated (radiation) oncologists and surgeons. He 
integrates different roles; nursing care, expert, consultant, education, 
research and nursing leadership. This focusses on particular prob-
lems seem in lung cancer and mesothelioma patients. He forms a link 
between outpatient clinic and clinical care, performing all medical 
actions that are written in dedicated protocols and consulting medical 
specialists for situations that go beyond the protocols. He prescribes 
medication under supervision of medical specialists. He is especially 
equiped to integrate complex medical-social problems and counseling 
for patients and their families. In the clinic, he educates and supports 
the nursing staff conserning speciﬁc lung cancer related issues, like 
nebulization and pleural ﬂuid drainage. He is actively involved in 
medical research, e.g. setting-up the study logistics, informing and sup-
porting patients in the study. 
Conclusion: The nurse practitioner is a fairly new profession in the 
Netherlands Cancer Institute. This profession creates a good balance 
between nursing care and medical care. From the patient’s point of 
view it is important that the integrated care is given by one profession-
al. He is allowed to prescribing medication, although political debate 
on this problem is still ongoing.
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Concordance Between Recommendations of a Multidisciplinary 
Thoracic Oncology Conference and Actual Clinical Practice
Osarogiagbon, Raymond U. Kronish, Lori E. Thompson, Lesley N. 
University of Tennessee Cancer Institute, Memphis, TN, USA
Background: Management of patients with lung cancer requires the 
involvement of multiple specialists. A multidisciplinary approach to 
care is advocated to facilitate shared-decision making which can im-
prove the quality of care. Setting up multidisciplinary clinics is difﬁcult 
because of the number of different specialists needed and their widely 
disparate work schedules. A multidisciplinary thoracic oncology con-
ference (MD-TOC) involving the key specialists is potentially a way of 
achieving the beneﬁts of multidisciplinary care. However, the effective-
ness of this approach depends on compliance with recommendations. 
We report our experience with patients presented to a new MD-TOC at 
the Methodist University Hospital, Memphis TN, a tertiary healthcare 
teaching facility in the USA. The period of analysis spans the time from 
inauguration of the conference in February 2006 to January 2007. 
Methods: Descriptive retrospective comparison of MD-TOC recom-
mendations and actual clinical management of consecutive patients. 
MD-TOC participants included a thoracic surgeon, pulmonologist, 
medical oncologist, radiation oncologist, pathologist and radiolo-
gist. Actual clinical management information was obtained from an 
electronic medical record system at the University of Tennessee Cancer 
Institute. MD-TOC recommendations were obtained from meeting 
logs. This study was approved by the Institutional Review Board of the 
University of Tennessee.
Results: Fifty two patients were presented, 28 females and 24 males, 
median age was 63 years (range 43 to 77). The patients were repre-
sentative of an urban population in the southern US, with 35 African 
American, 14 caucasian, 2 hispanic and 1 native American. Employ-
ment status was as follows: 6 employed, 13 unemployed, 16 retired, 
3 disabled, 13 unknown, 1 prison inmate. The health care payor 
characteristics were as follows: 21 with commercial insurance, 6 with 
medicare 6; 3 with medicaid 3; 20 with no insurance, 1 unknown and 1 
‘other’.
Nine of 52 patients had no diagnosed cancer: 2 expired before biopsy, 2 
had benign lung lesions, 3 refused biopsy and 2 were lost to followup. 
Forty-three patients (82.7%) were diagnosed with cancer with the fol-
lowing histology: adenocarcinoma 21 (49%), squamous cell 16 (37%), 
small cell 4 (9%), large cell neuroendocrine 1 (2%), bronchoalveolar 
cell carcinoma 1 (2%). Five of 43 patients (11.6%) were not clinically 
staged: 3 declined evaluation, 1 failed to followup, 1 patient was treated 
with chemotherapy without documented staging. Thirty-eight patients 
were clinically staged as follows: stage I, 6 (15.8%); II, 1 (2.6%); IIIA, 
6 (15.8%); IIIB, 12 (31.6%); IV, 13 (34.2%).
MDTOC recommendations and clinical concordance were as follows: 
18 patients were recommended for an invasive procedure, which was 
performed in 9 (50%). Nine of 18 patients (2 for surgical resection, 4 
for staging percutaneous CT-guided biopsy, 3 for staging mediastinos-
copy) did not undergo the recommended surgical procedure. Three of 
these nine patients declined the recommended procedure and received 
no treatment, 6 of 9 patients were treated with chemotherapy and/or 
radiation therapy without the recommended procedure. Of the 31 
patients for whom chemotherapy was recommended, 30 received treat-
ment, 1 patient declined and was lost to followup. Radiation therapy 
was recommended for 16 patients, all of whom received that modality 
of treatment. Participation in a clinical trial was recommended for 5 
patients, none participated.
Conclusions: There is a high level of concordance with non-surgical 
treatment recommendations of an MD-TOC, but relatively poor con-
cordance with recommendations for invasive staging procedures and 
surgical management. The reasons for this include patient and provider 
dissent. The multi-disciplinary thoracic oncology clinic environment, 
with active patient participation, may be a better model to ensure bet-
ter concordance with evidence-based recommendations and clinical 
practice.
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Clinical relevance of symptom change during chemotherapy for 
advanced non-small-cell lung cancer
Cella, David1 Eton, David1 Hensing, Thomas1 Masters, Gregory2  
Parasuraman, Bhash3 
1 Evanston Northwestern Healthcare & Feinberg School of Medicine, 
Northwestern University, Evanston, IL, USA 2 Helen Graham Cancer 
Center, Newark, DE, USA 3 Astrazeneca, Wilmington, DE, USA 
Background: The objective of this study was to identify which symp-
toms commonly associated with advanced non-small-cell lung cancer 
(NSCLC) are most likely to change (worsen or improve) in association 
